Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Capital Expenditures (2016 - 2026)

Intellia Therapeutics has reported Capital Expenditures over the past 12 years, most recently at $79000.0 for Q1 2026.

  • Quarterly Capital Expenditures fell 3.66% to $79000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $29000.0 through Mar 2026, up 101.57% year-over-year, with the annual reading at $32000.0 for FY2025, 94.45% down from the prior year.
  • Capital Expenditures was $79000.0 for Q1 2026 at Intellia Therapeutics, up from $32000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $4.3 million in Q2 2023 and troughed at -$6.6 million in Q3 2023.
  • The 5-year median for Capital Expenditures is $885000.0 (2022), against an average of $985687.5.
  • Year-over-year, Capital Expenditures surged 312.99% in 2022 and then plummeted 15529.63% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $3.9 million in 2022, then crashed by 100.69% to -$27000.0 in 2023, then plummeted by 15529.63% to -$4.2 million in 2024, then soared by 100.76% to $32000.0 in 2025, then skyrocketed by 146.88% to $79000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Capital Expenditures are $79000.0 (Q1 2026), $32000.0 (Q4 2025), and -$82000.0 (Q2 2025).